The Health Benefits of Calcium Citrate Malate: a Review of the Supporting Science
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
WO 2013/096420 Al 27 June 2013 (27.06.2013) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/096420 Al 27 June 2013 (27.06.2013) P O P C T (51) International Patent Classification: (72) Inventors; and A23L 1/236 (2006.01) (71) Applicants (for US only): PRAKASH, Indra [US/US]; 9750 Talisman Drive, Alpharetta, GA 30022 (US). (21) International Application Number: MARKOSYAN, Avetik [AM/MY]; A-5-8 Park Resid PCT/US2012/070562 ence, an 112h, Kuala Lumpur, 59200 (MY). (22) International Filing Date: CHATURVEDULLA, Venkata, Sai Prakash [IN/US]; 19 December 2012 (I 12.2012) 13300 Morris Road, Unit 107, Alpharetta, GA 30004 (US). CAMPBELL, Mary [US/US]; 5 171 Proctor Landing, Ac- (25) Filing Language: English worth, GA 30101 (US). SAN MIGUEL, Rafael [US/US]; (26) Publication Language: English 3277 Craggy Point, Se, Atlanta, GA 30339 (US). PURKAYASTHA, Siddhartha [US/US]; 615 Glenwood (30) Priority Data: Lane, Lombard, IL 60148 (US). JOHNSON, Marquita 61/577,202 19 December 201 1 (19. 12.201 1) US [US/US]; 10133 South Karlov Ave., Oak Lawn, IL 60453 61/65 1,099 24 May 2012 (24.05.2012) US (US). (71) Applicants (for all designated States except US): THE (74) Agents: KAUFMAN, Rebecca et al; King & Spalding, COCA-COLA COMPANY [US/US]; One Coca-Cola 1180 Peachtree Street, Atlanta, GA 30309 (US). Plaza, NW, Atlanta, GA 303 13 (US). PURECIRCLE SDN BHD [MY/MY]; PT 23419, Lengkuk Teknologi, (81) Designated States (unless otherwise indicated, for every Techpark @ ENSTEK, 71760 Bandar ENSTEK, Negeri kind of national protection available): AE, AG, AL, AM, Sembilan (MY). -
Magnesium Malate, Used As a Novel Food Ingredient and As A
SCIENTIFIC OPINION ADOPTED: 15 May 2018 doi: 10.2903/j.efsa.2018.5292 Evaluation of di-magnesium malate, used as a novel food ingredient and as a source of magnesium in foods for the general population, food supplements, total diet replacement for weight control and food for special medical purposes EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Maged Younes, Peter Aggett, Fernando Aguilar, Riccardo Crebelli, Birgit Dusemund, Metka Filipic, Maria Jose Frutos, Pierre Galtier, Ursula Gundert-Remy, Gunter Georg Kuhnle, Claude Lambre, Jean-Charles Leblanc, Inger Therese Lillegaard, Peter Moldeus, Alicja Mortensen, Agneta Oskarsson, Ivan Stankovic, Ine Waalkens-Berendsen, Rudolf Antonius Woutersen, Matthew Wright, Harry McArdle, Paul Tobback, Fabiola Pizzo, Ana Rincon, Camilla Smeraldi and David Gott Abstract The present scientific opinion deals with the evaluation of the safety of di-magnesium malate (DMM) proposed as a novel food ingredient and as a source of magnesium for use in foods for the general population, food supplements, total diet replacement for weight control and food for special medical purposes (FSMP), and with the bioavailability of magnesium from this source. Additional information was sought from the applicant during the assessment process. However, despite several requests, the applicant did not provide the additional data. Consequently, the Panel performed this assessment on the basis of the available data and concluded that there was insufficient scientific evidence of a difference between the proposed novel food ingredient named as DMM and magnesium malate already authorised as a source of magnesium included in Annex II to Directive 2002/46/EC. Accordingly, the Panel was unable to assess the safety of DMM as a novel food ingredient. -
Bioavailability and Solubility of Different Calcium-Salts As a Basis for Calcium Enrichment of Beverages
Food and Nutrition Sciences, 2010, 1, 53-58 53 doi:10.4236/fns.2010.12009 Published Online October 2010 (http://www.SciRP.org/journal/fns) Bioavailability and Solubility of Different Calcium-Salts as a Basis for Calcium Enrichment of Beverages Gaby Kressel*, Maike Wolters, Andreas Hahn Institute of Food Science and Human Nutrition, Leibniz University of Hannover, Hannover, Germany. Email: [email protected] Received July 13th, 2010; revised August 26th, 2010; accepted October 9th, 2010. ABSTRACT Background: When usual calcium consumption patterns were analysed most people in the U.S. and Europe consume less than the recommended daily allowance. Supplements and fortified foods offer alternative and additional sources of calcium to traditional food. Calcium carbonate is the most common supplement but it is less soluble in water and, therefore, not suitable for enrichment of beverages. New organic calcium salts have a better solubility but less is known about their bioavailability. In the present study, we assessed the solubility and bioavailability of the new organic cal- cium salts, calcium lactate citrate and calcium lactate malate, in comparison to the traditional supplements, calcium carbonate and calcium gluconate. Design: Randomized, single-blind, four way cross-over study comparing single doses of 500 mg calcium in the form of four different calcium-salts. Subjects were advised to consume 25 µg vitamin D3 daily two weeks prior to the start of the study and during the whole study period. Subjects: 20 healthy young men, Methods: Blood samples were drawn immediately before and 2, 4, 6, 8, 12 and 24 h after ingestion of the calcium preparation. -
Attachment A2
Attachment A2 Draft variation to the Australia New Zealand Food Standards Code (Volume 2, Schedules S1 to S30) – Proposal P1025 Code Revision Australia New Zealand Food Standards Code Food Standards Australia New Zealand Act 1991 Volume 2, Schedules 1 to 30 Contents Schedule 1—RDIs and ESADDIs 7 S1.01 RDIs and ESADDIs for vitamins .......................................................... 7 S1.02 RDIs and ESADDIs for minerals ..........................................................8 S1.03 Calculation of retinol equivalents for carotene forms of vitamin A ........ 8 S1.04 Calculation of alpha-tocopherol equivalents for vitamin E .................... 9 Schedule 2—Units of measurement 10 S2.01 Units of measurement........................................................................ 10 Schedule 3—Identity and purity 12 S3.01 Substances with specifications in primary sources ............................ 12 S3.02 Substances with specifications in secondary sources ........................ 13 S3.03 Additional and supplementary requirements ...................................... 13 S3.04 Specifications for Advantame ............................................................ 14 S3.05 Specification for agarose ion exchange resin .................................... 14 S3.06 Specification for bentonite ................................................................. 15 S3.07 Specification for bromo-chloro-dimethylhydantoin ............................. 15 S3.08 Specification for carboxymethyl cellulose ion exchange resin ............ 16 -
Australia New Zealand Food Standards Code This Version
Australia New Zealand Food Standards Code Food Standards Australia New Zealand Act 1991 This Code consists of standards made under the Food Standards Australia New Zealand Act 1991. As in effect on [date of commencement] DRAFT This version contains amendments up to Amendment No. 148. Contents Australia New Zealand Food Standards Code 231 Schedule 1 RDIs and ESADDIsError! Reference source not found.Section S1—1 Name Schedules of the Code Schedule 1 RDIs and ESADDIs Note 1 This instrument is a standard under the Food Standards Australia New Zealand Act 1991 (Cth). The standards together make up the Australia New Zealand Food Standards Code. See also section 1.1.1—3. Standard 1.1.1 relates to introductory matters and standards that apply to all foods. This Standard specifies RDIs and ESADDIs for section 1.1.2—10. Note 2 The provisions of the Code that apply in New Zealand are incorporated by reference into a food standard under the Food Act 1981 (NZ). See also section 1.1.1—3. S1—1 Name This Standard is Australia New Zealand Food Standards Code — Schedule 1 — RDIs and ESADDIs. Note Commencement: This Standard commences on [date of commencement], being the date specified as the commencement date in notices in the Gazette and the New Zealand Gazette under section 92 of the Food Standards Australia New Zealand Act 1991 (Cth). See also section 93 of that Act. Australia New Zealand Food Standards Code 232 Schedule 1 RDIs and ESADDIsError! Reference source not found.Section S1—2 RDIs and ESADDIs for vitamins S1—2 RDIs and ESADDIs for vitamins -
Calcium Citrate Malate Composition
~" ' MM II II II MM II II III I Ml II I II J European Patent Office _ _ _ -•#»>■ © Publication number: 0 533 724 B1 Office_„. europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 26.04.95 © Int. CI.6: C07C 59/265, A61 K 31/1 9, C07C 59/245, C07C 51/41 © Application number: 91910588.2 @ Date of filing: 30.05.91 © International application number: PCT/US91/03779 © International publication number: WO 91/19692 (26.12.91 91/29) Q») CALCIUM CITRATE MALATE COMPOSITION. © Priority: 14.06.90 US 537313 © Proprietor: THE PROCTER & GAMBLE COM- 31.10.90 US 608055 PANY One Procter & Gamble Plaza @ Date of publication of application: Cincinnati 31.03.93 Bulletin 93/13 Ohio 45202 (US) © Publication of the grant of the patent: @ Inventor: FOX, Mary, Mora 26.04.95 Bulletin 95/17 13 Applewood Dr. Fairfield, OH 45014 (US) © Designated Contracting States: Inventor: HECKERT, David, Clinton AT BE DE FR GB IT NL 3561 Kehr Road Oxford, OH 45056 (US) © References cited: Inventor: LUHRSEN, Kenneth, Ray EP-A- 0 297 679 Route 1, Box 11 EP-A- 0 304 987 Aurora, IN 47001 (US) © Representative: Canonlcl, Jean-Jacques et al Procter & Gamble European Technical Cen- ter N.V. 00 Temselaan 100 ^ B-1853 Strombeek-Bever (BE) CM 00 00 w Note: Within nine months from the publication of the mention of the grant of the European patent, any person ® may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition CL shall be filed in a written reasoned statement.